TY - JOUR
T1 - Acute myeloid leukaemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis
T2 - Result of an ECOG database analysis
AU - the Eastern Cooperative Oncology Group
AU - Paietta, Elisabeth
AU - Andersen, Janet
AU - Yunis, Jorge
AU - Rowe, Jacob M.
AU - Cassileth, Peter A.
AU - Tallman, Martin S.
AU - Bennett, John M.
AU - Wiernik, Peter H.
N1 - Publisher Copyright:
© 1998 Blackwell Science Ltd.
PY - 1998
Y1 - 1998
N2 - While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult acute myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as 32% positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41% of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML had a low response rate (54%) when compared with acute monocytic leukaemia (AMOL; 82%, P=0.006) or AML overall (68%, P=0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.
AB - While assessing the prognostic implications of immunophenotyping in 382 patients enrolled in treatment protocols of the Eastern Cooperative Oncology Group (ECOG) for de novo adult acute myeloid leukaemia, we identified 95 patients with a unique antigen profile characterized by high expression of the leucocyte integrin CD11b (CD11b+ AML). High expression of CD11b was defined as 32% positive blasts based on the retrospectively established prognostic cut-off point for this antigen. Although CD11b is normally expressed by mature monocytes, natural killer cells and granulocytes, leukaemic blasts in CD11b+ AML lacked other immunologic monocytic features (e.g. CD14 and CD122, the interleukin-2 receptor β chain) and demonstrated a high degree of immaturity, as reflected by a high incidence of blasts expressing the stem cell factor receptor, CD117, and few blasts positive for the myeloid differentiation antigen CD15. Furthermore, by FAB criteria, only 41% of CD11b+ AML cases were classified as M4/M5. Patients with CD11b+ AML had a low response rate (54%) when compared with acute monocytic leukaemia (AMOL; 82%, P=0.006) or AML overall (68%, P=0.031), independent of age, cytogenetic abnormalities and P-glycoprotein expression. Because of its poor prognosis, recognition of CD11b+ AML is clinically warranted and, given its morphologic and cytogenetic ambiguity, must be based on the unique antigen profile.
KW - Adult AML
KW - CD11b
KW - New subtype
UR - http://www.scopus.com/inward/record.url?scp=0031990847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031990847&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1998.00561.x
DO - 10.1046/j.1365-2141.1998.00561.x
M3 - Article
C2 - 9488612
AN - SCOPUS:0031990847
SN - 0007-1048
VL - 100
SP - 265
EP - 272
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -